Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
Total Assets
Immunoprecise Antibodies Ltd
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Total Assets
CA$67m
|
CAGR 3-Years
40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Total Assets
$1.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Total Assets
CA$321.8k
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovotech Inc
XTSX:IOT
|
Total Assets
CA$3.4m
|
CAGR 3-Years
39%
|
CAGR 5-Years
31%
|
CAGR 10-Years
31%
|
|
Immunoprecise Antibodies Ltd
Glance View
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Vancouver, British Columbia and currently employs 73 full-time employees. The firm is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The firm offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies.
See Also
What is Immunoprecise Antibodies Ltd's Total Assets?
Total Assets
67m
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Total Assets amounts to 67m CAD.
What is Immunoprecise Antibodies Ltd's Total Assets growth rate?
Total Assets CAGR 3Y
40%
Over the last year, the Total Assets growth was 146%. The average annual Total Assets growth rates for Immunoprecise Antibodies Ltd have been 40% over the past three years .
